Dr Sarah Psutka speaks to ecancer about perioperative outcomes of neoadjuvant TAR-200 plus cetrelimab (CET) or CET alone in patients with muscle-invasive bladder cancer ineligible for or refusing neoadjuvant cisplatin-based chemotherapy.

The SunRISe-4 trial investigates outcomes for muscle-invasive bladder cancer by comparing a neoadjuvant strategy using a PD-1 inhibitor alone versus in combination with the TAR-200 device.

An interim analysis of 76 patients shows promising results, with a higher pathologic complete response rate for the combination therapy and limited toxicity.

The trial aims to provide alternatives for patients ineligible for standard cisplatin-based chemotherapy.